COLLEGIUM PHARMACEUTICAL, INC — Director's Dealing 2015

May 6, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK: 0001267565
Period of Report: 2015-05-06

Reporting Person: Hirsch David (Director, 10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Convertible Preferred Stock	$		Common Stock (1860570)		Indirect
Series B Convertible Preferred Stock	$		Common Stock (37290)		Indirect
Series C Convertible Preferred Stock	$		Common Stock (458102)		Indirect
Series C Convertible Preferred Stock	$		Common Stock (9182)		Indirect
Series D Convertible Preferred Stock	$		Common Stock (731214)		Indirect
Series D Convertible Preferred Stock	$		Common Stock (14656)		Indirect

Footnotes

F1: All series of Convertible Preferred Stock will automatically convert into Collegium Pharmaceutical, Inc. common stock on a 1-for-6.9 basis immediately prior to the closing of the initial public offering and have no expiration date.

F2: The shares are held by Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P. (collectively, the "Longitude Funds"). Longitude Capital Partners, LLC is the general partner of the Longitude Funds and may be deemed to have sole voting investment and dispositive power over the shares held by the Longitude Funds. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of Longitude Capital Partners, LLC and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by the reporting persons. David Hirsch is a member of Longitude Capital Partners, LLC. Dr. Hirsch disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.